The investment conglomerate reported a higher-than-expected profit, aided by a recovery in its te ...

By Twesha Dikshit (Reuters) -European stocks edged higher on Friday, led by upbeat corporate earnings and a jump in Novo ...

The investment conglomerate reported a higher-than-expected profit, aided by a recovery in its te ...

CNBC's Silvia Amaro takes a look at the rise and fall in Novo Nordisk shares. Donald Trump's executive order changing 401 ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

Rather, it was the Danish pharmaceutical company's No. 1 rival. Appreciative investors bid up Novo Nordisk's stock in a ...

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

Novo Nordisk A/S climbed 3.72% during Friday's pre-market trading session, after rival Eli Lilly 's Phase 3 ATTAIN-1 trial for obesity drug, orforglipron trailed the Danish drug giant's semaglutide.

Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn ...

Lilly's second-quarter results reported Thursday were still more than fine: $15.5 billion in revenue beat Wall Street ...

Eli Lilly’s orforglipron cut body weight to a lesser extent than rival Novo Nordisk’s semaglutide, falling into analysts’ ...

Investing.com - Copenhagen-listed shares of Novo Nordisk (CSE:NOVOb) rose by more than 5% on Friday, extending gains notched in the prior session, after a weight-loss pill from chief rival Eli Lilly ...